8-K Announcements
6Material company update
May 28, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 10, 2026·SEC
Celularity Inc.(CELU)Earnings, Financials & Key Ratios
CELU•NASDAQ
Price updated Jun 19, 2026
AboutCelularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.Show more
- Revenue$27M-51.0%
- EBITDA-$54M-77.5%
- Net Income-$92M-58.6%
- EPS (Diluted)-3.59-35.7%
- Gross Margin76.04%+5.1%
- EBITDA Margin-203.44%-262.4%
- Operating Margin-230.92%-226.4%
- Net Margin-345.76%-223.8%
CELU Key Insights
Celularity Inc. (CELU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 15.1%
- ✓Strong 5Y sales CAGR of 13.2%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 16.9% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CELU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CELU Price & Volume
Celularity Inc. (CELU) stock price & volume — 10-year historical chart
Loading chart...
CELU Growth Metrics
Celularity Inc. (CELU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years13.21%
3 Years13.88%
TTM-51.03%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-58.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-39.22%
Return on Capital
10 Years-61.66%
5 Years-58.51%
3 Years-86%
Last Year-116.14%
CELU Peer Comparison
Celularity Inc. (CELU) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 SANA | 876.62M | 3.15 | -3.28 | -161.87% | 0.49 | |||
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 | ||
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare CELU vs Peers
Celularity Inc. (CELU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CELU Income Statement
Celularity Inc. (CELU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 17.55M | 21.15M | 14.28M | 21.34M | 17.98M | 22.77M | 54.22M | 26.55M |
Revenue Growth % | - | 20.47% | -32.48% | 49.43% | -15.75% | 26.68% | 138.11% | -51.03% |
Cost of Goods Sold | 6.55M | 6.32M | 4.93M | 9.65M | 19.66M | 16.02M | 14.99M | 6.36M |
COGS % of Revenue | 37.34% | 29.9% | 34.54% | 45.24% | 109.4% | 70.34% | 27.64% | 23.96% |
Gross Profit | 11M▲ 0% | 14.82M▲ 34.8% | 9.35M▼ 36.9% | 11.68M▲ 25.0% | -1.69M▼ 114.5% | 6.75M▲ 499.7% | 39.23M▲ 480.8% | 20.19M▼ 48.5% |
Gross Margin % | 62.66% | 70.09% | 65.46% | 54.76% | -9.4% | 29.66% | 72.36% | 76.04% |
Gross Profit Growth % | - | 34.77% | -36.95% | 24.99% | -114.47% | 499.7% | 480.77% | -48.54% |
Operating Expenses | 1.1K | 278.95M | 161.27M | 120.74M | 23.91M | 199.04M | 77.59M | 81.5M |
OpEx % of Revenue | 0.01% | 1319.11% | 1129.51% | 565.93% | 133.02% | 874.1% | 143.1% | 306.95% |
Selling, General & Admin | 1.1K | 41.79M | 31.34M | 71.34M | 66.02M | 50.58M | 58.64M | 51.27M |
SG&A % of Revenue | 0.01% | 197.62% | 219.47% | 334.38% | 367.29% | 222.11% | 108.16% | 193.09% |
Research & Development | 29.06M | 46.05M | 52.71M | 88.35M | 78.36M | 30.46M | 17.39M | 15.03M |
R&D % of Revenue | 165.56% | 217.77% | 369.15% | 414.12% | 435.96% | 133.79% | 32.07% | 56.59% |
Other Operating Expenses | -31.6M | 191.11M | 77.23M | -38.95M | -120.47M | 118M | 1.56M | 15.21M |
Operating Income | -1.1K▲ 0% | -264.13M▼ 24055364.5% | -151.93M▲ 42.5% | -109.06M▲ 28.2% | -25.6M▲ 76.5% | -192.29M▼ 651.1% | -38.36M▲ 80.1% | -61.31M▼ 59.8% |
Operating Margin % | -0.01% | -1249.01% | -1064.05% | -511.17% | -142.42% | -844.44% | -70.75% | -230.92% |
Operating Income Growth % | - | -24055364.48% | 42.48% | 28.22% | 76.53% | -651.12% | 80.05% | -59.83% |
EBITDA | 4.79M | -257.94M | -143.75M | -100.24M | -16.16M | -182.96M | -30.44M | -54.01M |
EBITDA Margin % | 27.28% | -1219.76% | -1006.8% | -469.85% | -89.92% | -803.49% | -56.13% | -203.44% |
EBITDA Growth % | - | -5486.27% | 44.27% | 30.27% | 83.88% | -1031.92% | 83.36% | -77.46% |
D&A (Non-Cash Add-back) | 4.79M | 6.19M | 8.17M | 8.82M | 9.44M | 9.32M | 7.92M | 7.29M |
EBIT | -1.1K | -77.16M | -210.58M | -96.93M | -148.27M | -193.27M | -51.63M | -84.96M |
Net Interest Income | 0 | 694K | -1.98M | -2.84M | 365K | -2.69M | -5.93M | -6.49M |
Interest Income | 628K | 694K | 370K | 332K | 365K | 320K | 331K | 262K |
Interest Expense | 0 | 0 | 2.35M | 3.17M | 0 | 3.02M | 6.26M | 6.75M |
Other Income/Expense | 2 | -3.87M | -61.01M | 8.96M | 39.8M | -4M | -19.53M | -30.41M |
Pretax Income | -1.1K▲ 0% | -267.99M▼ 24407368.1% | -212.93M▲ 20.5% | -100.1M▲ 53.0% | 14.21M▲ 114.2% | -196.28M▼ 1481.8% | -57.89M▲ 70.5% | -91.71M▼ 58.4% |
Pretax Margin % | -0.01% | -1267.29% | -1491.34% | -469.17% | 79.03% | -862% | -106.77% | -345.44% |
Income Tax | 0 | -56.11M | -4.7M | 20K | 13K | 10K | 0 | 3K |
Effective Tax Rate % | 0% | 20.94% | 2.21% | -0.02% | 0.09% | -0.01% | 0% | -0% |
Net Income | -1.1K▲ 0% | -211.88M▼ 19296894.5% | -208.23M▲ 1.7% | -100.12M▲ 51.9% | 14.19M▲ 114.2% | -196.29M▼ 1483.1% | -57.89M▲ 70.5% | -91.8M▼ 58.6% |
Net Margin % | -0.01% | -1001.94% | -1458.42% | -469.27% | 78.95% | -862.04% | -106.77% | -345.76% |
Net Income Growth % | - | -19296894.54% | 1.72% | 51.92% | 114.18% | -1483.14% | 70.51% | -58.57% |
Net Income (Continuing) | -1.1K | -211.88M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M | -91.72M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.00▲ 0% | -88.75▲ 0% | -113.06▼ 27.4% | -7.87▲ 93.0% | 0.95▲ 112.0% | -11.02▼ 1263.4% | -2.64▲ 76.0% | -3.59▼ 35.7% |
EPS Growth % | - | - | -27.39% | 93.04% | 112.04% | -1263.4% | 76% | -35.75% |
EPS (Basic) | 0.00 | -88.75 | -113.06 | -7.87 | 1.01 | -11.02 | -2.64 | -3.59 |
Diluted Shares Outstanding | 3.59M | 2.39M | 1.84M | 12.73M | 14.98M | 17.81M | 21.89M | 25.6M |
Basic Shares Outstanding | 3.59M | 2.39M | 1.84M | 12.73M | 13.99M | 17.81M | 21.89M | 25.6M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CELU Balance Sheet
Celularity Inc. (CELU) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 24.71K | 36.81M | 72.16M | 59.1M | 33.5M | 19.79M | 20.56M | 12.32M |
Cash & Short-Term Investments | 24.71K | 28.13M | 54.31M | 37.24M | 13.97M | 227K | 738K | 6.17M |
Cash Only | 24.71K | 28.13M | 54.31M | 37.24M | 13.97M | 227K | 738K | 6.17M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.92M | 3.08M | 6.55M | 5.23M | 6.97M | 12.12M | 13.56M | 4.65M |
Days Sales Outstanding | 81.49 | 53.13 | 167.44 | 89.53 | 141.45 | 194.24 | 91.26 | 63.97 |
Inventory | 3.54M | 3.23M | 3.85M | 9.55M | 5.31M | 5.75M | 5.41M | 571K |
Days Inventory Outstanding | 196.89 | 186.54 | 284.93 | 361.07 | 98.52 | 131.11 | 131.72 | 32.76 |
Other Current Assets | 1.49M | 480K | 873K | 2K | 1.05M | 0 | 857K | 222K |
Total Non-Current Assets | 532.17M | 484.69M | 358.85M | 355.03M | 367.56M | 124.1M | 112.12M | 95.01M |
Property, Plant & Equipment | 4.01M | 66.39M | 90.08M | 90.63M | 88.72M | 78.82M | 72.43M | 66.52M |
Fixed Asset Turnover | 4.38x | 0.32x | 0.16x | 0.24x | 0.20x | 0.29x | 0.75x | 0.40x |
Goodwill | 130.64M | 127.07M | 123.3M | 123.3M | 119.69M | 7.35M | 7.35M | 7.35M |
Intangible Assets | 393.71M | 271.47M | 125.38M | 123.19M | 120.99M | 11M | 9.25M | 7.76M |
Long-Term Investments | 0 | 291M | 15.2M | 14.84M | 14.84M | 9.94M | 10.24M | 0 |
Other Non-Current Assets | 3.81M | -271.24M | 4.89M | 3.08M | 23.32M | 26.93M | 12.86M | 13.39M |
Total Assets | 24.71K▲ 0% | 521.5M▲ 2110617.6% | 431.01M▼ 17.4% | 414.13M▼ 3.9% | 401.07M▼ 3.2% | 143.89M▼ 64.1% | 132.68M▼ 7.8% | 107.33M▼ 19.1% |
Asset Turnover | 710.49x | 0.04x | 0.03x | 0.05x | 0.04x | 0.16x | 0.41x | 0.25x |
Asset Growth % | - | 2110617.61% | -17.35% | -3.92% | -3.15% | -64.12% | -7.79% | -19.11% |
Total Current Liabilities | 150.56K | 20.64M | 26.68M | 26.23M | 62.09M | 67.3M | 53.68M | 80.76M |
Accounts Payable | 5.27M | 18.88K | 5.39M | 9.32M | 5.81M | 14.14M | 23.3M | 26.42M |
Days Payables Outstanding | 293.34 | 1.09 | 398.89 | 352.3 | 107.84 | 322.34 | 567.29 | 1.52K |
Short-Term Debt | 0 | 0 | 3.01M | 3.05M | 37.6M | 39.24M | 6.36M | 14M |
Deferred Revenue (Current) | 0 | 0 | 5.12M | 2.2M | 2.27M | 2.83M | 3.53M | 5.25M |
Other Current Liabilities | -10.74M | 11.23M | 8.17M | 7.83M | 13.83M | 8.07M | 1.6M | 6.92M |
Current Ratio | 0.16x | 1.78x | 2.70x | 2.25x | 0.54x | 0.29x | 0.38x | 0.15x |
Quick Ratio | -23.32x | 1.63x | 2.56x | 1.89x | 0.45x | 0.21x | 0.28x | 0.15x |
Cash Conversion Cycle | -14.95 | 238.58 | 53.47 | 98.3 | 132.13 | 3.01 | -344.31 | -1.42K |
Total Non-Current Liabilities | 0 | 363M | 385.62M | 288.48M | 140.08M | 35.63M | 70.17M | 64.63M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 35.93M | 0 |
Capital Lease Obligations | 0 | 28.06M | 27.63M | 28.09M | 27.98M | 26.18M | 26.55M | 26.9M |
Deferred Tax Liabilities | 0 | 0 | 7K | 10K | 9K | 9K | 9K | 12K |
Other Non-Current Liabilities | 0 | 334.94M | 350.36M | 258.52M | 109.86M | 6.26M | 4.96M | 34.92M |
Total Liabilities | 150.56K | 383.63M | 412.3M | 314.71M | 202.16M | 102.93M | 123.84M | 145.39M |
Total Debt | 150K | 28.06M | 30.64M | 31.14M | 65.59M | 65.42M | 68.84M | 40.9M |
Net Debt | 125.29K | -66K | -23.67M | -6.1M | 51.62M | 65.19M | 68.1M | 34.73M |
Debt / Equity | - | 0.20x | 1.64x | 0.31x | 0.33x | 1.60x | 7.79x | - |
Debt / EBITDA | 0.03x | - | - | - | - | - | - | - |
Net Debt / EBITDA | 0.03x | - | - | - | - | - | - | - |
Interest Coverage | - | - | -89.46x | -30.57x | - | -64.10x | -8.24x | -12.58x |
Total Equity | -125.85K▲ 0% | 137.86M▲ 109647.3% | 18.71M▼ 86.4% | 99.42M▲ 431.3% | 198.9M▲ 100.1% | 40.96M▼ 79.4% | 8.84M▼ 78.4% | -38.06M▼ 530.7% |
Equity Growth % | - | 109647.31% | -86.43% | 431.28% | 100.07% | -79.41% | -78.43% | -530.71% |
Book Value per Share | -0.04 | 57.75 | 10.16 | 7.81 | 13.28 | 2.30 | 0.40 | -1.49 |
Total Shareholders' Equity | -125.85K | 137.86M | 18.71M | 99.42M | 198.9M | 40.96M | 8.84M | -38.06M |
Common Stock | 863 | 1K | 1K | 12K | 15K | 19K | 2K | 3K |
Retained Earnings | -1.1K | -355.33M | -563.56M | -663.68M | -645.5M | -841.79M | -899.68M | -991.48M |
Treasury Stock | 0 | 0 | -256K | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -149.75K | 0 | 0 | 0 | 9K | 0 | -5K | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CELU Cash Flow Statement
Celularity Inc. (CELU) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -543 | -1.1M | -63.19M | -110.1M | -137.88M | -38.69M | -6.4M | -13.25M |
Operating CF Margin % | -0% | -5.19% | -442.59% | -516.03% | -767.04% | -169.89% | -11.81% | -49.92% |
Operating CF Growth % | - | -202079.19% | -5656.16% | -74.22% | -25.23% | 71.94% | 83.45% | -107.06% |
Net Income | -13.38M | 5.88M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M | -91.72M |
Depreciation & Amortization | 4.79M | 0 | 8.17M | 8.82M | 9.44M | 11.47M | 7.92M | 7.29M |
Stock-Based Compensation | 4.5M | 0 | 4.37M | 40.01M | 15.86M | 15.02M | 11.57M | 10.38M |
Deferred Taxes | 0 | -1.65K | -8.48M | 0 | 0 | 0 | 0 | 3K |
Other Non-Cash Items | -54.54M | -7.11M | 137.37M | -53.1M | -161.91M | 137.89M | 9.8M | 27.19M |
Working Capital Changes | -1.34M | 136.39K | 3.6M | -5.71M | -15.45M | -6.77M | 22.2M | 33.59M |
Change in Receivables | -2.29M | 0 | 1.65M | -1.91M | -3.58M | -6.83M | -3.97M | 7.55M |
Change in Inventory | -3.4M | 0 | -643K | -6.42M | -16.89M | -865K | 6.28M | 10.25M |
Change in Payables | 0 | 18.88K | 314K | 0 | 0 | 0 | 9.24M | 3.13M |
Cash from Investing | -31.18M | -286.85M | -12.81M | -5.9M | -5.24M | -4.05M | 514K | 0 |
Capital Expenditures | -1.92M | 0 | -27.83M | -6.2M | -5.24M | -4.05M | -161K | 0 |
CapEx % of Revenue | 10.93% | 0% | 194.94% | 29.07% | 29.13% | 17.78% | 0.3% | - |
Acquisitions | -29.28M | 0 | 15.02M | 0 | 0 | 0 | -1.5M | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 14K | 651K | 0 | 300K | 0 | 0 | 2.17M | 0 |
Cash from Financing | 25.25K | 288.84M | 102.01M | 98.56M | 119.84M | 24.09M | 6.7M | 18.65M |
Debt Issued (Net) | 0 | -150K | 0 | 0 | 39.2M | 11.31M | 7.1M | -121K |
Equity Issued (Net) | 25K | 288.99M | 102.28M | 638K | 53.37M | 5.43M | 58K | 24.41M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.9M |
Share Repurchases | 0 | 0 | -256K | 0 | 0 | 0 | 0 | 0 |
Other Financing | 250 | 0 | -265K | 97.92M | 27.26M | 7.35M | -459K | 255K |
Net Change in Cash | -31.16M▲ 0% | 892.3K▲ 102.9% | 26.01M▲ 2814.5% | -17.44M▼ 167.0% | -23.27M▼ 33.5% | -18.64M▲ 19.9% | 814K▲ 104.4% | 5.39M▲ 562.8% |
Free Cash Flow | -1.92M▲ 0% | -1.1M▲ 42.8% | -91.03M▼ 8191.5% | -116.3M▼ 27.8% | -143.11M▼ 23.1% | -42.73M▲ 70.1% | -6.56M▲ 84.6% | -13.25M▼ 102.0% |
FCF Margin % | -10.93% | -5.19% | -637.53% | -545.11% | -796.17% | -187.66% | -12.1% | -49.92% |
FCF Growth % | - | 42.78% | -8191.54% | -27.76% | -23.06% | 70.14% | 84.64% | -101.98% |
FCF per Share | -0.53 | -0.46 | -49.42 | -9.14 | -9.55 | -2.40 | -0.30 | -0.52 |
FCF Conversion (FCF/Net Income) | 0.49x | 0.01x | 0.30x | 1.10x | -9.72x | 0.20x | 0.11x | 0.14x |
Interest Paid | 0 | 0 | 0 | 146K | 0 | 1.07M | 144K | 2.5M |
Taxes Paid | 0 | 0 | 13K | 0 | 0 | 0 | 0 | 52K |
CELU Key Ratios
Celularity Inc. (CELU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -307.66% | -265.99% | -169.5% | 9.51% | -163.67% | -232.51% | - |
Return on Invested Capital (ROIC) | - | -287.52% | -171.55% | -185.14% | -11.17% | -80.87% | -31.43% | -124.95% |
Gross Margin | 62.66% | 70.09% | 65.46% | 54.76% | -9.4% | 29.66% | 72.36% | 76.04% |
Net Margin | -0.01% | -1001.94% | -1458.42% | -469.27% | 78.95% | -862.04% | -106.77% | -345.76% |
Debt / Equity | - | 0.20x | 1.64x | 0.31x | 0.33x | 1.60x | 7.79x | - |
Interest Coverage | - | - | -89.46x | -30.57x | - | -64.10x | -8.24x | -12.58x |
FCF Conversion | 0.49x | 0.01x | 0.30x | 1.10x | -9.72x | 0.20x | 0.11x | 0.14x |
Revenue Growth | - | 20.47% | -32.48% | 49.43% | -15.75% | 26.68% | 138.11% | -51.03% |
Related:CELU Dividend History·CELU Revenue History·CELU Price History·CELU P/E History·CELU Financial Ratios·CELU Institutional Holders
CELU SEC Filings & Documents
Celularity Inc. (CELU) SEC filings — annual & quarterly reports (10-K, 10-Q)
CELU Frequently Asked Questions
Celularity Inc. (CELU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Celularity Inc. (CELU) reported $26.6M in revenue for fiscal year 2025. This represents a 51% increase from $17.6M in 2018.
Celularity Inc. (CELU) saw revenue decline by 51.0% over the past year.
Celularity Inc. (CELU) reported a net loss of $91.7M for fiscal year 2025.
Dividend & Returns
Yes, Celularity Inc. (CELU) pays a dividend with a yield of 30.64%. This makes it attractive for income-focused investors.
Celularity Inc. (CELU) had negative free cash flow of $13.3M in fiscal year 2025, likely due to heavy capital investments.